B
Braizon Therapeutics
Nanotechnology drug delivery platform for CNS diseases
About Braizon Therapeutics
Braizon Therapeutics, Inc. is a Japanese biotechnology company established on October 30, 2015, that is developing a drug delivery system (DDS) to overcome the blood-brain barrier (BBB). The company's core technology, Brain Access®, is a platform that uses nanoparticles to transport therapeutic compounds to the central nervous system (CNS) to treat diseases like Alzheimer's. The company was founded by venture capital group Fast Track Initiative. Its founding technology was the result of a collaboration between Professor Kazunori Kataoka of the University of Tokyo and Professor Takanori Yokota of the Tokyo Medical and Dental University. Mariko Tosu is a founder and previously served as CEO, with Philip Davy currently holding the CEO position.
The company's primary focus is on addressing the challenge of delivering drugs to the brain, which is protected by the highly selective BBB. Braizon's technology encapsulates drugs within glucose-labeled nanoparticles, or micelles, which can cross the BBB. The company is also developing a second-generation system that utilizes the transferrin receptor (TfR) pathway, which would not require glycemic control. This platform is versatile and can carry various therapeutic molecules, including nucleic acid medicines, antibodies, and low-molecular-weight compounds.
Braizon Therapeutics' business model centers on licensing its Brain Access® platform to pharmaceutical and biotechnology companies, as well as academic institutions. These partners can then use the technology to develop new therapies for CNS disorders. The company also has its own pipeline of treatments in development. Braizon has research and development divisions in Kawasaki, Japan, and Cambridge, Massachusetts, USA. Since its founding, the company has secured funding from investors including Fast Track Initiative, The University of Tokyo Cooperative Platform Development Co., Ltd., and SMBC Venture Capital Co., Ltd. In March 2016, the company raised 106 million yen in a Series A round, followed by a Series B round of 645 million yen in July 2018. Another funding round in July 2021 brought in 300 million yen.
Source: Dealroom company dataNews
Open roles
Braizon Therapeutics in the Tokyo ecosystem
The Braizon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Fast Track Initiative
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Braizon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Braizon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

